Exemple: Heart Attack

Recherche d'essais cliniques pour: Copolymer 1

111 résultats au total

NCT03982212

Recrutement

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Conditions: Cutaneous Squamous Cell Carcinoma; Squamous Cell Carcinoma; Basal Cell Carcinoma
NCT03209479

Recrutement

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Conditions: Multiple Sclerosis
NCT02153723

Terminé

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Conditions: Rett Syndrome
NCT01167426

Terminé

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Conditions: Multiple Sclerosis
NCT02499900

Terminé

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Conditions: Multiple Sclerosis
NCT00203021

Terminé

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Conditions: Relapsing-Remitting Multiple Sclerosis
NCT00910598

Statut inconnu

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Conditions: Multiple Sclerosis
NCT00203073

Terminé

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Conditions: Relapsing Remitting Multiple Sclerosis
NCT00203112

Terminé

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Conditions: Relapse Remitting Multiple Sclerosis
NCT01578785

Interrompue

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Conditions: Relapsing-Remitting Multiple Sclerosis
NCT00337779

Terminé

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Conditions: Relapsing Remitting Multiple Sclerosis
NCT01936129

Statut inconnu

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Conditions: Glaucoma, Angle-closure, Primary, Acute
NCT00666224

Terminé

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

Conditions: Multiple Sclerosis
NCT00240032

Terminé

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Conditions: Multiple Sclerosis
NCT00819195

Terminé

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT00937157

Terminé

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Conditions: Multiple Sclerosis
NCT00856635

Terminé

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Conditions: Optic Neuritis
NCT01067521

Terminé

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Conditions: Relapsing Remitting Multiple Sclerosis
NCT02023424

Statut inconnu

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Conditions: Rett Syndrome
NCT00202982

Terminé

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Conditions: Relapse-Remitting Multiple Sclerosis
NCT00239993

Terminé

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

Conditions: Multiple Sclerosis
NCT02753088

Terminé

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Conditions: Relapsing-remitting Multiple Sclerosis
NCT00677664

Statut inconnu

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

Conditions: Diabetic Retinopathy
NCT01569451

Terminé

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Conditions: Multiple Sclerosis
NCT00176592

Statut inconnu

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

Conditions: Multiple Sclerosis